<DOC>
	<DOCNO>NCT00403234</DOCNO>
	<brief_summary>The objective study evaluate : ( 1 ) efficacy buprenorphine transdermal system ( BTDS , Butransâ„¢ ) postoperative pain follow total knee replacement surgery ; ( 2 ) impact BTDS functional rehabilitative measure total knee replacement surgery ; 3 ) safety BTDS total knee replacement surgery . The double-blind treatment period 28 day time supplemental analgesic medication provide subject addition study drug . Purdue Pharma L.P. terminate trial early due administrative reason relate efficacy safety . The focus study become safety evaluation .</brief_summary>
	<brief_title>Safety Buprenorphine Transdermal System ( BTDS ) Subjects With Acute Postoperative Pain After Total Knee Replacement</brief_title>
	<detailed_description>Buprenorphine synthetic opioid analgesic 25 year international clinical experience indicate safe effective variety therapeutic situation relief moderate severe pain .</detailed_description>
	<mesh_term>Pain , Postoperative</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>Males females 18 80 year age American Society Anesthesiologists ( ASA ) physical status classification 1 , 2 3 Scheduled undergo unilateral total knee arthroplasty ( TKA ) treatment osteoarthritis . Subjects pain disability site operative joint . Subjects total knee arthroplasty within 6 month schedule surgery schedule undergo bilateral knee arthroplasty . Subjects whose body mass index ( BMI ) 40 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Postoperative pain</keyword>
	<keyword>opioid</keyword>
	<keyword>transdermal</keyword>
	<keyword>TKA ( total knee arthroplasty )</keyword>
</DOC>